Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755157 | 0.97 | HTT (0.48) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL21259228 | 0.97 | HTT (0.48) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL20746932 | 0.97 | HTT (0.48) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL19334136 | 0.97 | HTT (0.48) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL19522401 | 0.97 | HTT (0.48) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL18816226 | 0.95 | HTT (0.47) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL21538501 | 0.94 | HTT (0.47) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL23879489 | 0.91 | ALDH1A1 (0.49) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL10290163 | 0.91 | ALDH1A1 (0.49) | HTTMEN1KMT2ALMNAPOLB | |
| SCHEMBL19522460 | 0.85 | L3MBTL1 (0.44) | MEN1KMT2AALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| CN-1322524-A | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| CN-1100408-A | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | CN | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8569058-B2 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569608-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569609-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070043114-A1 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-7176240-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176240-B2 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1685832-A1 | NERVE REGENERATION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043114-A1 | Nerve regeneration promoters | BDNF, NGF, GAP43 | HTT 1098/4885MEN1 3868/4885KMT2A 3212/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | HTT 153/4885MEN1 3222/4885KMT2A 3904/4885 |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | HTT 471/4885MEN1 685/4885KMT2A 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.